Time to Debunk an Urban Myth? The “Abscopal Effect” With Radiation and Anti–PD-1
In the article that accompanies this editorial, McBride et al 1 report a well-executed study that has broader implications beyond head and neck cancer (HNC) and speaks to larger issues of combination therapies in the era of cancer immunotherapy. Briefly, patients with metastatic HNC, including 3 biologic entities (human papillomavirus [HPV]–positive; Epstein-Barr [EBV]–positive; and tobacco-associated/nonviral HNC), were randomly assigned 1:1 to anti–PD-1 therapy alone and anti–PD-1 therapy in combination
